Wound dressings for the controlled release of therapeutic agents

Patent metadata

Field	Value
Publication number	US-10307505-B2
Application number	US-201715612831-A
Country	US
Kind code	B2
Filing date	Jun 2, 2017
Priority date	Nov 24, 2003
Publication date	Jun 4, 2019
Grant date	Jun 4, 2019

Abstract

A wound dressing material for controlled activation of a wound healing therapeutic compound in the presence of a protease enzyme in a wound fluid, the material comprising: a medically acceptable polymer; a wound healing therapeutic agent; an inhibitor of the protease enzyme; and a linker group which is cleavable by the protease enzyme wherein the activities of both the wound healing therapeutic agent and the inhibitor increased by contacting the wound dressing material with a would fluid containing the protease enzyme. For example, the enzyme may be a matrix metalloproteinase, the therapeutic agent may be a reactive oxygen scavenger, and the inhibitor may be a tissue inhibitor of metalloproteinase (TIMP).

First claim

What is claimed is:

1. A wound dressing material for controlled activation of a wound healing therapeutic compound in the presence of a protease in a wound fluid, the material comprising:
a medically acceptable polymer cross-linked by an oligopeptidic sequence;
a therapeutic agent comprising a reactive oxygen scavenger selected from the group consisting of antioxidant phenol derivatives, vitamin E, methyl peroxide antioxidants, stilbenes, gallocatechins, ubiquinol, retinoids, vitamin A, vitamin C, N-acetyl cysteine, selenium and its compounds, zinc and its compounds, glutathione, carotenoids, papai, thioproline, albumin, chlorophyllin, antioxidant dyestuffs, and mixture or any two or more thereof; and
an inhibitor of the protease;
wherein
the oligopeptidic sequence is cleavable by the protease and is a substrate for the protease;
the therapeutic agent and the inhibitor are dispersed in a matrix of the medically acceptable polymer; and
the activities of both the therapeutic agent and the inhibitor are increased by contacting the wound dressing material with a wound fluid containing the protease.

2. A wound dressing material according to claim 1 wherein elevated levels of the protease are associated with pain, wound infection or wound chronicity.

3. A wound dressing material according to claim 1 , wherein the protease is elastase and wherein the oligopeptidic sequence comprises lys-gly-ala-ala-ala-lys-Ala-Ala-Ala-, Ala-Ala-Pro-Val, Ala-Ala-Pro-Leu, Ala-Ala-Pro-Phe, Ala-Ala-Pro-Ala or Ala-Tyr-Leu-Val.

4. A wound dressing material according to claim 1 , wherein the protease is a matrix metalloproteinase and wherein the oligopeptidic sequence comprises -Gly-Pro-Y- Gly-Pro-Z-, -Gly-Pro-Leu-Gly-Pro-Z-, -Gly-Pro-Ile-Gly-Pro-Z-, or-Ala-Pro-Gly-Leu-Z-, where Y and Z are amino acids.

5. A wound dressing material according to claim 1 , wherein the protease is a collagenase and wherein the oligopeptidic sequence comprises -Pro-Leu-Gly-Pro-D-Arg- Z-, -Pro-Leu-Gly-Leu-Leu-Gly-Z-, -Pro-Gln-Gly-Ile-Ala-Gly-Trp-, -Pro-Leu-Gly-Cys (Me)- His-,-Pro-Leu-Gly-Leu-Trp-Ala-, -Pro-Leu-Ala-Leu-Trp-Ala-Arg-, or -Pro-Leu-Ala-Tyr-Trp-Ala-Arg-, where Z is an amino acid.

6. A wound dressing material according to claim 1 , wherein the protease is a gelatinase and wherein the oligopeptidic sequence comprises -Pro-Leu-Gly-Met-Trp-Ser-Arg-.

7. A wound dressing material according to claim 1 , wherein the protease is thrombin and wherein the oligopeptidic sequence comprises -Gly-Arg-Gly-Asp-, -Gly-Gly-Arg-, -Gly-Arg-Gly-Asp-Asn-Pro-, -Gly-Arg-Gly-Asp-Ser-, -Gly-Arg-Gly-Asp-Ser-Pro-Lys-, -Gly-Pro-Arg-, -Val-Pro-Arg-, or -Phe-Val-Arg-.

8. A wound dressing material according to claim 1 , wherein the protease is stromelysin and wherein the oligopeptidic sequence comprises -Pro-Tyr-Ala-Tyr-Trp-Met-Arg-.

9. A wound dressing material according to claim 1 wherein the therapeutic agent further comprises an antimicrobial agent, a pain relieving agent, an antiseptic, an analgesic, or a local anaesthetic.

10. A wound dressing material according to claim 1 , wherein the inhibitor is selected from the group consisting of Tissue Inhibitor of Metalloproteinase (TIMP), 4-(2-aminoethyl) benzenesulfonyl fluoride AEBSF, antithrombin, (p-Amidinophenyl) methanesulfonyl fluoride APMSF, Aprotinin, diisopropylfluorophosphate DFP, phenyl methyl sulfonyl fluoride PMSF, Antipain, Chymostatin, Leupeptin, Tosyl-lysine chloromethylketone TLCK, Tosyl-phenyl chloromethylketone TPCK, L-trans-epoxysuccinylleucylamido (4-guanidino) butane E-64, Amastatin, Bestatin, Diprotin, Ethylenediamine tetra-acetic acid (EDTA), pepstatin and mixtures thereof.

11. A wound dressing comprising a wound dressing material according to claim 1 .

12. A wound dressing material according to claim 1 , wherein the medically acceptable polymer comprises an elastin.

13. A wound dressing material according to claim 1 , wherein the medically acceptable polymer comprises N-(2-hydroxypropyl)methacrylamide cross-linked with the linker group.

14. A wound dressing material according to claim 1 , wherein the medically acceptable polymer comprises chitosan.

Assignees

• Kci Usa Inc

Inventors

• Cullen Breda Mary
• Gregory Sara Jayne

Classifications

• A61L15/32 Primary

  Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin {(A61L15/225 takes precedence)} · CPC title

• A61L15/18

  containing inorganic materials · CPC title

• A61L2300/412

  Tissue-regenerating or healing or proliferative agents · CPC title

• A61L2300/45

  Mixtures of two or more drugs, e.g. synergistic mixtures · CPC title

• A61L2300/434

  of enzymes · CPC title